[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454326":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":19,"locations":30,"responsibleParty":50,"collaborators":52,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":9,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"NIP IT!",null,"Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival\u002Ffresh tumor specimens will be collected for banking and future research purposes.",[13,17],{"name":14,"affiliation":15,"role":16},"Lillian Siu, MD","Princess Margaret Hospital, Canada","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":15,"role":16},"Philippe Bedard, MD",[20,26],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Celeste Yu, MSc","CONTACT","416-946-4501","5281","celeste.yu@uhn.ca",{"name":27,"role":22,"phone":23,"phoneExt":28,"email":29},"Elizabeth Shah","3833","elizabeth.shah@uhn.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-79.39864,43.70643,{"lat":43,"lon":42},[46,48,49],{"name":47,"role":22,"phone":23,"phoneExt":24,"email":25},"Celeste Yu",{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"name":18,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[53],{"name":15,"class":6},"100454326","non-invasive-artificial-intelligence-based-platform-monitoring-program-nip-it-100454326",false,"NCT05196087","Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)","Inclusion Criteria:\n\n1. Patients with histological confirmation of a solid tumor.\n2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":63,"type":64},500,"ESTIMATED","OBSERVATIONAL","Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.",[68,69,70],"Breast Cancer","Melanoma","Gastrointestinal Neuroendocrine Tumor",[72,73,74,75],"Molecular Profiling","Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","2025-06-27",{"date":78,"type":79},"2025-07-02","ACTUAL",{"date":81,"type":79},"2022-07-20",{"date":83,"type":64},"2027-06",{"name":5,"class":6},1]